Aeolus Pharmaceuticals reports Barda's exercises of USD3m in additional contract funding for development of AEOL 10150 for Acute Radiation Syndrome.
M2 PHARMA-June 29, 2015-Aeolus Pharmaceuticals reports Barda's exercises of USD3m in additional contract funding for development of AEOL 10150 for Acute Radiation Syndrome
(C)2015 M2 COMMUNICATIONS
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) disclosed on Friday the exercise of USD3m in additional contract options for AEOL 10150 by Biomedical Advanced Research and Development Authority (BARDA) under the USD118m advanced research and development contract.
According to the company, its lead compound, AEOL 10150, is being developed for the treatment of pulmonary syndrome of Acute Radiation Syndrome (Lung-ARS) and delayed effects of acute radiation exposure (DEARE) under a contract with BARDA.
This agreement will collect data necessary for an approval under the US FDA "Animal Rule" and for a pre-Emergency Use Authorization (EUA) filing. The approval or pre-EUA would allow the federal government to buy AEOL 10150 for the Strategic National Stockpile under the Pandemic All-Hazards Preparedness Reauthorization Act (PAHPRA) to accelerate the research, development, purchase and availability of effective medical countermeasures for the Strategic National Stockpile.
BARDA's options include funding for the laboratory work suggested by the US FDA as a pathway to removing the clinical hold on the IND for AEOL 10150 in Lung-ARS aswell as ongoing animal studies to optimise the administration of AEOL 10150 for Lung-ARS, including duration of treatment and delayed treatment studies.
AEOL 10150 is a broad-spectrum catalytic antioxidant specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation and subsequent tissue damage-signaling cascades resulting from radiation exposure, concluded the company.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 29, 2015|
|Previous Article:||Biogen and Sobi partnership discloses EMA's MAA for ALPROLIX for treating hemophilia B.|
|Next Article:||Sanguine proposes change in name to New Alliance BioSciences to reflect its broader scope of research and development activities.|